Drug Trial Radar · NCT04187560
Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Dec 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Jan 22, 2020
Primary completion
Jul 1, 2020
Study completion Nov 9, 2020
Sponsor
- Lead sponsor
- LB Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Single Ascending Dose (SAD; Part A) and Multiple Ascending Dose (MAD; Part B) Phase 1 Study of LB-102 N-Methyl amisulpride) in healthy volunteers. The primary objective is to evaluate the safety and the tolerability of a single oral dose (SAD) and multiple oral doses (MAD) of LB-102 as compared to placebo. The secondary objectives are to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of LB-102.
Conditions
- Schizophrenia
Interventions
LB-102Drug
(N-Methyl amisulpride)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants who experience at least one treatment-emergent adverse event (TEAE)Time frame: Day 8 (Part A) or Day 15 (Part B)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medpace Clinical Pharmacology LLC
Cincinnati, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.